Perineural invasion (PNI) refers to cancer cells growing along or into the sheath surrounding nerves within the prostate. When detected in a biopsy sample, PNI indicates that the cancer has found a pathway along nerve structures that could facilitate its spread beyond the prostate gland.
Prostate cancer is the second most common malignancy in men worldwide and the sixth leading cause of cancer-related death globally. Accurate staging before surgery is critical because it determines the type and intensity of treatment a patient receives. Key staging tools include serum PSA levels, the Gleason score (which grades cancer aggressiveness from biopsy tissue), and imaging studies.
Treatment decisions for localized prostate cancer depend on classifying patients by risk - low, intermediate, or high. For patients with good prognostic factors, the probability of treatment failure after surgery or radiotherapy is around 10%. For patients with poor prognostic factors, the probability of recurrence within five years can reach 40-50%. The question this study asks is whether PNI detected on biopsy should factor into this risk stratification.
Prior research on the prognostic significance of PNI has been contradictory. Some studies found PNI associated with extra-prostate invasion and higher tumor stages; others found it added no independent predictive value beyond PSA, Gleason score, and clinical stage. This study aimed to clarify the relationship by comparing biopsy and post-surgical pathology findings in 109 patients.
This was a cross-sectional study enrolling 109 patients who underwent radical prostatectomy at a tertiary care center between 2008 and 2013. All patients had preoperative prostate needle biopsies with recorded Gleason scores spanning three ranges: less than 6, 7, and 8-10. The presence or absence of PNI in each biopsy specimen was documented.
Following surgery, the entire removed prostate was examined by pathology. The surgical pathology Gleason score and pathological tumor stage (T-stage) were compared against the preoperative biopsy Gleason score and clinical stage. This allowed measurement of the rates of concordance (biopsy and surgical pathology agreed), under-staging (biopsy underestimated the disease), and over-staging (biopsy overestimated the disease).
The primary comparison was between patients with PNI (28 patients, 25.7% of the cohort) and those without PNI (81 patients, 74.3%). Statistical analysis used Chi-square and Mann-Whitney-U tests, with statistical significance set at p less than 0.05. Patients with incomplete records were excluded.
Of the 109 patients, 28 (25.7%) had PNI on biopsy. The groups with and without PNI were well matched at baseline: mean age (65.1 vs. 66.5 years), mean PSA level (10.7 vs. 11.7 ng/mL), and mean biopsy Gleason score (6.5 vs. 6.1) were all similar with no statistically significant differences (all p greater than 0.05).
The overall concordance between biopsy Gleason score and post-surgical Gleason score was only 36.7% - meaning in nearly two-thirds of cases, the biopsy score did not match the final pathological score from the removed prostate. Concordance was somewhat better in the PNI group (46.4%) than the non-PNI group (33.3%), but this difference was not statistically significant.
Regarding pathological tumor stage after surgery, patients with PNI had significantly higher stages. T1 and T2 (cancer confined to the prostate) were found in 75% of PNI patients, compared to 93.8% of non-PNI patients (p = 0.024). Among the 12 patients with extra-prostate involvement (stages T3-T4), 7 (58.3%) had PNI on biopsy, compared to only 21.6% with PNI among those whose cancer remained organ-confined (p = 0.012).
Despite this association with higher stage, there were no significant differences between PNI and non-PNI groups in rates of under-staging (biopsy missed more advanced disease) or over-staging. Overall, under-staging was extremely common in this cohort: 72.5% of patients were under-staged clinically, with clinical and pathological stages concordant in only 11% of cases.
Multiple prior studies have examined whether PNI predicts extra-prostate cancer spread. Several large analyses - including those by D'Amico, O'Malley, Freedland, Bismar, Tsuzuki, and Cannon - found that PNI was not an independent prognostic factor for pathological stage, cancer recurrence, or long-term survival when controlling for PSA, Gleason score, and other variables. Notably, Freedland's multivariate analysis identified the percentage of malignant tissue in the biopsy as the strongest prognostic factor, with PNI not independently predicting recurrence.
A minority of studies have found PNI to be an independent predictor. De la Taille and colleagues found PNI, combined with PSA and Gleason score, to be an independent predictor of pT3 (extra-prostate) disease. Sebo et al. similarly identified PNI as one of several independent predictors of extra-prostate involvement. Loeb et al. found PNI significantly associated with worse prognosis and extra-prostate spread in multivariate analysis.
One important practical application for PNI detection, regardless of its prognostic staging value, relates to surgical planning. Bastacky et al. reported that PNI had 27% sensitivity but 96% specificity for predicting extra-prostate involvement - meaning it rarely flags cancer that isn't spreading, but catches only a small fraction of spreading cases. This high specificity could still help surgeons decide whether to spare or remove neurovascular bundles on the side of PNI-positive biopsies during nerve-sparing radical prostatectomy.
The wide range of PNI frequency (11-38%) across studies likely reflects different biopsy protocols, tissue preparation methods, and definitions of PNI. The present study found a frequency of 25.7%, consistent with the reported range. The authors identify several reasons for the controversy in the literature: variable definitions of PNI, different criteria for extra-prostate involvement, and varied PSA thresholds used to define disease progression after surgery.
One of the most striking findings in this study is the dramatic rate of under-staging: 72.5% of patients had their cancer under-staged by preoperative clinical assessment. Only 11% of patients showed concordance between clinical staging and final post-surgical pathological staging. This underscores a fundamental challenge in prostate cancer management - the limitations of biopsy-based assessment.
The low overall Gleason score concordance of 36.7% between biopsy and surgical pathology reflects the multifocal nature of prostate cancer. A needle biopsy samples only a small portion of the prostate, and the highest-grade areas of a heterogeneous tumor may be missed. This means many patients are receiving treatment decisions based on incomplete information about their actual cancer grade and stage.
Among patients without PNI, Gleason score concordance varied significantly by Gleason category: patients with Gleason 7 on biopsy had 63.6% concordance, while those with Gleason 8-10 had only 25% concordance. This suggests that high-grade cancers are particularly difficult to accurately grade by biopsy alone. In contrast, among patients with PNI, concordance rates did not differ significantly by Gleason category, suggesting PNI may introduce additional diagnostic complexity.
The study confirms that PNI detected on prostate needle biopsy is associated with higher post-surgical tumor stages - patients with PNI were significantly more likely to have cancer that had spread beyond the prostate. However, when assessed alongside PSA levels, Gleason scores, and clinical staging, PNI did not function as an independent predictor of staging discordance or overall risk category.
The authors conclude that PNI alone is not an appropriate independent factor for risk stratification in treatment decision-making. Treatment type and intensity should continue to be determined primarily by PSA level, Gleason score, clinical staging, and other established risk factors rather than PNI status alone.
Key limitations include the absence of follow-up data (preventing comparison with actual treatment outcomes), the focus on only one treatment modality (radical prostatectomy), and the lack of quantitative assessment of PNI extent (only presence or absence was recorded). Future studies should include PNI quantification (number of nerves involved, percentage of cores with PNI), long-term outcome data, and comparison across different treatment modalities to more definitively settle the prognostic question.